News Releases

SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that the

– Completed successful IPO raising approximately $80.0 million in gross proceeds – – NDA for TRUDHESA for treatment of acute migraine accepted for review by FDA; PDUFA date of September 6, 2021 – – Strengthened commercial capabilities with expanded management team and strategic collaboration with

Data Will Evaluate Exploratory Efficacy Data from STOP-301 Study Evaluating INP104 Consistency of Response, Recurrence and Sustained Response Findings Also Highlight Safety and Tolerability Including Nausea and Nasal and Cardiovascular Safety as a Promising Potential New Option for the Treatment of

Initiative Features Artwork from Internationally Renowned Artist Ed Fairburn, Specially Developed to Illustrate the Complexities of Migraine SEATTLE, May 18, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma (Nasdaq: IMPL), a late-stage biopharmaceutical company, today launched Reroute Migraine Relief ,

SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced

Leonard S. Paolillo Appointed as Chief Commercial Officer, Gerald F. Penn Appointed as Vice President, Market Access & Trade Significant Leadership Experience Continues Build Out of Impel’s Commercial Strategy, Infrastructure and Market Access Capabilities as Company Advances Go-To-Market Strategy

Impel adopting Veeva software, data, and consulting to accelerate pre-launch planning and digital-first commercial execution SEATTLE and PLEASANTON, CA — February 10, 2021  —   Impel NeuroPharma  and  Veeva Systems  (NYSE: VEEV) today announced a strategic partnership as Impel continues advancing

FDA Conditionally Accepts Trade Name, TRUDHESA™, Pending Approval of the NDA, and Sets PDUFA Goal Date of September 6, 2021 Company’s Lead Candidate is Based on Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology, and is the First and Only Delivery System to Explore the Vascular-Rich